Breathe Biomedical Incis A Medical Technology Company Dedicated To Enhancing Early Disease Detection Through Breath Based Diagnosticswith Headquarters In Monctonnew Brunswickand Cambridgemassachusettsthe Company Focuses On Developing Non Invasive Breath Analytics To Identify Disease Related Biomarkersparticularly For Breast Cancer Detection The Company Operates Under An Iso 13485 Certified Quality Management Systemensuring High Standards For Medical Device Safety And Efficacyits Proprietary Breath Analytics Platform Detects Volatile Organic Compounds In Exhaled Breathserving As An Adjunct To Traditional Mammographyespecially For Women With Dense Breast Tissuebreathe Biomedical Is Currently Conducting A Multi Center Observational Study In Collaboration With George Washington University Breast Center To Validate Its Breath Test Breathe Biomedical Completed An Ipo In 2024 To Support Research And Developmentmarket Expansionand Operational Scalingthe Company Is Also Focused On Global Expansion And Forming Partnerships With Biotech Firms And Research Institutionsits Core Values Include Communicationintegrityinnovationcollaborationand Accountabilityall Aimed At Improving Patient Outcomes
